Fagron NV (EBR:FAGR)
20.60
+0.15 (0.73%)
Oct 29, 2025, 1:09 PM CET
Fagron NV Revenue
Fagron NV had revenue of 476.13M EUR in the half year ending June 30, 2025, with 28.14% growth. This brings the company's revenue in the last twelve months to 918.75M, up 11.94% year-over-year. In the year 2024, Fagron NV had annual revenue of 871.96M with 14.28% growth.
Revenue (ttm)
918.75M
Revenue Growth
+11.94%
P/S Ratio
1.63
Revenue / Employee
230.32K
Employees
3,828
Market Cap
1.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 871.96M | 108.97M | 14.28% |
| Dec 31, 2023 | 762.99M | 79.11M | 11.57% |
| Dec 31, 2022 | 683.88M | 110.07M | 19.18% |
| Dec 31, 2021 | 573.81M | 17.84M | 3.21% |
| Dec 31, 2020 | 555.97M | 21.28M | 3.98% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 6.85B |
| argenx SE | 2.66B |
| Ion Beam Applications | 585.76M |
| European Medical Solutions | 49.47M |
| Biocartis Group NV | 47.69M |
| Hyloris Pharmaceuticals | 8.46M |
| Nyxoah | 4.93M |
| Onward Medical | 2.72M |
Fagron NV News
- 19 days ago - Fagron NV (ARSUF) Q3 2025 Sales Call Transcript - Seeking Alpha
- 20 days ago - Fagron NV (ARSUF) Q3 2025 Sales/ Trading Statement Call - Slideshow - Seeking Alpha
- 20 days ago - Fagron reports solid third quarter performance with 6.4% revenue growth and confirms full year outlook - GlobeNewsWire
- 5 months ago - Fagron increases share capital through exercise subscription rights - GlobeNewsWire
- 6 months ago - Fagron: Recent Capital Markets Day Confirms Upside Potential - Seeking Alpha
- 7 months ago - Record first-quarter revenue of €239 million, reflecting 14% topline growth - GlobeNewsWire
- 10 months ago - Fagron: FDA Warning Letter Creates New Entry Opportunity - Seeking Alpha
- 1 year ago - Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlook - GlobeNewsWire